New PET tracers could sharpen cancer detection
NCT ID NCT07630961
First seen Jun 09, 2026 · Last updated Jun 13, 2026 · Updated 1 time
Summary
This early-phase study is testing two new radioactive imaging agents (JFI447 and FFG233) to see how well they light up different solid tumors on PET scans. About 66 adults with advanced cancers like pancreatic, lung, breast, colorectal, or sarcoma will receive the agents and undergo imaging. The goal is to compare the agents' safety and ability to detect tumors, potentially improving how doctors diagnose and monitor these cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
RECRUITINGChuo Ku, Tokyo, 1040045, Japan
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.